Seit 2017
Stellvertretender Leiter Chirurgische Klinik

Seit 2010
Prüfungsexperte der Europäischen und Schweizerischen Gesellschaft für Urologie (Facharztprüfungen)

Seit 2006
Chefarzt Urologie am St. Claraspital, Basel

2005
Habilitation an der Universität Basel

2005
Aufbaukurs ‚Laparoskopie für Urologen’, Tuttlingen

2004
Forschungspreis der British Association of Urology ('Bob Krane International Prize')

2004
Strahlenschutzkurs für Ärzte, US Basel

2004
Managementkurs für leitende Spitalärzte, US Basel

2003
Wissenschaftspreis der Schweizerischen Gesellschaft für Urologie

2003
Kurs ‚Einführung in die Hochschul-Didaktik’, Basel

2002
Grundkurs ‚Laparoskopie für Urologen’, Strasbourg

2002
Schweizerischer Notärztekurs

2001-2006
Stv. Chefarzt Urologische Universitätsklinik beider Basel, Kantonsspital Liestal und Basel

1999-2000
Forschungsaufenthalt am Prostate Center' des Vancouver General Hospital, Kanada

1999
Facharzt-Titel Urologie FMH und EBU

1999
Praktisches Facharztexamen Urologie EBU, Warschau

1999
Praktisches Facharztexamen Urologie FMH, St.Gallen

1998
Kurs  ‚Molekularbiologie für Mediziner’, Bern

1997
Theoretisches Facharztexamen Urologie FMH und EBU

1995-1999
Urologie, Kantonsspital St.Gallen (ab 1998 als Oberarzt)

1994
Basisexamen Allgemeine Chirurgie

1992-1995
Allgemeinchirurgie, Kantonsspital Liestal

1991
ECFMG (US-Staatsexamen)

1991
Promotion an der Universität Basel

1984-1990
Medizinstudium an der Universität Basel

• Schweizerische Gesellschaft für Urologie
• Schweizerische Gesellschaft für Ultraschall in der Medizin
• Deutsche Gesellschaft für Urologie
• European Association of Urology

• Vlajnic T, Müller DC, Ruiz C, Schönegg R, Seifert HH, Thalmann GN, Zellweger T, Le Magnen C, Rentsch CA, Bubendorf L: Exploring the intratumoral heterogeneity of DNA-ploidy in prostate cancer. 2023 Cancer Reports.
• Bratic Hench I, Roma L, Conticelli F, Bubendorf L, Calgua B, Le Magnen C, Piscuoglio S, Rubin MA, Chirindel A, Nicolas GP, Vlajnic T, Zellweger T, Templeton AJ, Stenner F, Ruiz C, Rentsch C, Bubendorf L: Cell-Free DNA Genomic Profiling and its Clinical Implementation in Advanced Prostate Cancer. 2023: Cancers, 16: 45.
• Vlajnic T, Brunner P, Eppenberger-Castori S, Rentsch CA, Zellweger T, Bubendorf L: High Inter- and Intratumoral
  Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. Pathobiology 89(2): 74-80 (2022).
• Bacon JVW, Müller DC, Ritch E, Annala M, Dugas SG, Herberts C, Vandekerkhove G, Seifert H, Zellweger T, Black PC, Bubendorf L, Wyatt AW, Rentsch CA: Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. 2021: Eur Urol Oncol. 2588–9311(21): 00191–00197.
• Vlajnic T, Brunner P, Eppenberger-Castori S, Rentsch CA, Zellweger T, Bubendorf L: High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. 2021: Pathobiology: 1–7.
• Servant R, Garioni M, Vlajnic T, Blind M, Pueschel H, Müller DC, Zellweger T, Templeton AJ, Garofoli A, Maletti S, Piscuoglio S, Rubin MA, Seifert H, Rentsch CA, Bubendorf L, Le Magnen C: Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. 2021: J Pathol. 254(5): 543–555.
• Federer-Gsponer JR, Müller DC, Zellweger T, Eggimann M, Marston K, Ruiz C, Seifert HH, Rentsch CA, Bubendorf L, Le Magnen C. Patterns of stemness-associated markers in the development of castration-resistant prostate cancer. The Prostate 80(13): 1108–1117 (Sept. 2020)
• Dugas SG, Müller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW, Wyatt AW, Rentsch CA, Bubendorf L; Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathol.127(9): 578–585.
• Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M. Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression. PLoS One. 2018 Oct 15; 13(10).
• Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, Ruiz C. Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. J Pathol. 2018 May; 245(1): 74–84.
• Offermann A., Vlasic I., Syring I., Vogel W., Ruiz C., Zellweger T., Rentsch C., Hagedorn S., Behrends J., Nowak M., Merseburger A., Bubendorf L., Kirfel J., Duensing S., ShaikhibrahimZ.,Per-ner S.: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via-PI3K/mTOR signaling. Oncotarget. 10 Dec 2016
• Vedana M, Fuenfschilling M, Tzankov A, Zellweger T.: Primary synovial cell sarcoma of the kidney: case report and review of the literature. Case Rep Oncol. 2015 Mar 3;8(1):128-32.
• Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A, Ruiz C, Dirnhofer S, Bubendorf L, Rentsch CA: Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate. 2015 May;75(6):585-92. 
• Vlajnic T, Oeggerli M, Rentsch C, Püschel H, Zellweger T, Thalmann GN, Ruiz C, Bubendorf L.: Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Arch. 2014 Dec;465(6):637-42. 
• Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA.: Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up. Virchows Arch. 2014 Dec;465(6):629-36.
• Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. 2014 Aug;21(4):663-75.
• Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.: ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31.
• Shaikhibrahim Z., Offermann A., Braun M., Menon R., Syring I., Nowak M., Halbach R., Vogel W., Ruiz C., Zellweger T., Rentsch C.A., Svensson M., Andren O., Bubendorf L., Biskup S., Duensing S., Kirfel J., Perner S.: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. Aug 2014: 21(4): 663–75.
• Vlajnic T., Oeggerli M., Rentsch C., Püschel H., Zellweger T., Thalmann G.N., Ruiz C., Bubendorf L.: Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Arch. Dec 2014: 465(6): 637–42.
• Wetterauer C., Weibel M., Gsponer J.R., Vlajnic T., Zellweger T., Bütikofer S., Müller G., Püschel H., Bachmann A., Gasser T.C., Bubendorf L., Rentsch C.A.: Incidental prostate cancer prevalence at radical cystoprostatectomy – importance of the histopathological workup. Virchows Arch. Dec 2014: 465(6): 629–36.
• MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
  Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S. Int J Cancer. 2014 Jul 1;135(1):19-26.
• [Renal masses and indication to nephrectomy: preoperative assessment and clinical presentation of five cases]. Vedana M, Geisler S, Zellweger T, Gasser T.
  Rev Med Suisse. 2013 Nov 20;9(407):2184-8.
• Characterization and clinical relevance of ALDHbright populations in prostate cancer.
  Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.
  Clin Cancer Res. 2013 Oct 1;19(19):5361-71.
• Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.
  Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.
  Endocr Relat Cancer. 2013 May 21;20(3):403-13.
• ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.
  Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.
  Virchows Arch. 2012 Aug;461(2):157-62.
• High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
  Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.
  Prostate. 2012 Nov;72(15):1678-87.
• Zellweger T., Christ-Crain M.: Ist das Aging-Male-Syndrom noch aktuell? Swiss Medical Forum 11(51-52):979-980 (2011)
• Ruiz C., Lenkiewicz E., Evers L., Holley T., Robeson A., Kiefer J., Demeure M.J., Hollingsworth M.A., Shen M., Prunkard D., Rabinovitch P.S., Zellweger T., Mousses S., Trent J.M., Carpten J.D., Bubendorf L., Von Hoff D., Barrett M.T.: Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 108(29): 12054-9 (2011)
• Ruiz C., Holz D.R., Oeggerli M., Schneider S., Gonzales I.M., Kiefer J.M., Zellweger T., Bachmann A., Koivisto P.A., Helin H.J., Mousses S, Barrett M.T., Azorsa D.O., Bubendorf L.: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. Journal of Pathology 223(4): 543-52 (2011)
• Hailemariam S., Vosbeck J., Cathomas G., Zlobec I., Mattarelli G., Eichenberger T., Zellweger T., Bachmann A., Gasser T.C., Bubendorf L.: Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia? Human Patholology 42(5): 702-9 (2011)
• Zellweger T.: Was tun bei Hämaturie? Swiss Medical Forum 10 (51-52): 921-23 (2010)
• Ruiz C., Holz D.R., Oeggerli M., Schneider S., Gonzales I.M., Kiefer J.M., Zellweger T., Bachmann A., Koivisto P.A., Helin H.J., Mousses S., Barrett M.T., Azorsa D.O., Bubendorf L.: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. Journal of Pathology (2010) Nov. 25.
• Savic S., Zlobec I., Thalmann G.N., Engeler D., Schmauss M., Lehmann K., Mattarelli G., Eichenberger T., Dalquen P., Spieler P., Schoenegg R., Gasser T.C., Sulser T., Forster T., Zellweger T., Casella R., Bubendorf L.: The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International Journal of Cancer 124(12): 2899-904 (2009)
• Zellweger T., Günther S., Zlobec I., Savic S., Sauter G., Moch H., Mattarelli G., Eichenberger T., Curschellas E., Rüfenacht H., Bachmann A., Gasser T.C., Mihatsch M.J., Bubendorf L.: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. International Journal of Cancer 124(9): 2116-23 (2009)
• Zellweger T.: Prostatakarzinom im Frühstadium: Abwarten oder therapieren? Swiss Medical Forum 9 (51-52):958-959 (2009)
• Tan S.H., Dagvadorj A., Shen F., Gu L., Liao Z., Abdulghani J., Zhang Y., Gelmann E.P., Zellweger T., Culig Z., Visakorpi T., Bubendorf L., Kirken R.A., Karras J., Nevalainen M.T.: Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Research 68(1): 236-48 (2008)
• Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M.P., Zellweger T., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Nevalainen M.T.: Stat3 promotes metastatic progression of prostate cancer. American Journal of Pathology 172(6): 1717-28 (2008)
• Zellweger T.: Therapie des Nierenzellkarzinoms: Keine Revolution, aber viel Neues. Swiss Medical Forum 8 (51-52): 1023-1024 (2008)
• Dagvadorj A., Collins S., Jomain J.B., Abdulghani J., Karras J., Zellweger T., Li H., Nurmi M., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Goffin V., Nevalainen M.T.: Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 148(7): 3089-101 (2007)
• Zellweger T., Gasser T.: Urininkontinenz – wann welche Therapie? Swiss Medical Forum 1: 35-37 (2007)
• Zellweger T., Benz G., Cathomas G., Mihatsch M., Sulser T., Gasser T., Bubendorf L.: Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. International Journal of Cancer. 119(7): 1660-1665 (2006)
• Seiffert H.H., Mazzola B., Zellweger T., Ruszat R., Muller A., Burkhalter F., Steiger J., Sulser T., Bachmann A.: Ureteral obstruction after dextranomer/hyaluronic acid copolymer injection for treatment of secondary vesicoureteral reflux after renal transplantation. Urology 68(1): 203.e17-19 (2006)
• Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P.A., Mihatsch M.J., Gasser T.C., Bubendorf L.: Expression Patterns of Potential Therapeutic Targets in Prostate Cancer. International Journal of Cancer 113 (4): 619-628 (2005)
• Zellweger T., Gasser T.: Lokalisiertes Prostatakarzinom: Operieren, bestrahlen oder zuwarten? Praxis - Schweizerische Rundschau für Medizin 94(34):1307 -1308 (2005)
• Li H., Zhang Y., Glass A., Zellweger T., Gehan E., Bubendorf L., Gelmann E., Nevalainen M.T.: Activation of signal transducer and activator of transcription-5 (Stat5) in prostate cancer predicts early recurrence.  Clinical Cancer Research 11(16): 5863-5868 (2005)
• Zellweger T, Gasser T: Benigne Prostatahyperplasie: Hat das Messer ausgedient? Swiss Medical Forum 5: 1308-09 (2005)
• Zellweger T., Benz G., Herzog M., Grilli B., Mihatsch M., Gasser T., Bubendorf L.: FISH für eine verbesserte Abschätzung des Rezidivrisikos nach transurethraler Resektion von Urothelkarzinomen. Deutsche Gesellschaft für Pathologie 88, 194-198 (2004)
• Zellweger T., Ninck C., Mirlacher M., Glass A.G., Gasser T.C., Mihatsch M.J.,Gelmann E.P., Bubendorf L.: Tissue microarray analysis reveals prognostic importance of syndecan-1 expression in prostate cancer. The Prostate 55: 20-29 (2003)
• Kiyama S., Morrison K., Zellweger T., Akbari M, Cox M., Miyake H., Yu D.,Gleave M.E.: Antisense IGF-BP-2 oligonucleotides induceapoptosis and delay progression to androgen-independence after castration in human prostate cancer tumor models. Cancer Research 63 (13): 3575-3584 (2003)
• Zellweger T., Chi K., Kiyama S., Miyake H., Adomat H., Skov K., Gleave M.E.: Over-expression of the cell survival protein clusterin decreases radiosensitivity in the human LNCaP prostate tumor model. British Journal of Urology 92 (4): 463-469 (2003)
• Zellweger T., Gasser T.: PSA – Fluch oder Segen? Swiss Medical Forum 51/52: 1284-1286 (2003)
• July L., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E.: Clusterin expression is enhanced following androgen withdrawal therapy in prostate cancer patients. The Prostate 15; 50 (3): 179-188 (2002)
• Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., Gleave M.E.: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research 8 (10): 3276-3284 (2002)
• Zellweger T., Chi K., Miyake H., Kiyama S., July L.V., Akbari M., Gleave M.E.: Targeting cell survival genes using antisense oligonucleotides to improve chemo- and hormonal therapies in prostate cancer. European Urology Suppl. 1: 7-14 (2002)
• Gleave M., Zellweger T., Chi K., Miyake H., Kiyama S., July L., Leung S.: Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Investigative New Drugs 20 (2): 145-158 (2002)
• Leung S., Miyake H., Zellweger T., Gleave M.E.: Synergistic chemosensitization and inhibition of progression to androgen-independence by antisense bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. International Journal of Cancer 15; 91 (6): 846-850 (2001)
• Zellweger T., Miyake H., Cooper S., Conklin B., Monia B.P., Gleave M.E.: Pharmaco kinetics of antisense oligonucleotides is improved in vitro and in vivo by incorporation of 2‘-O-(2-methoxy) ethyl chemistry.  Journal of Pharmacology and Experimental Therapeutics 298 (3): 934-940 (2001)
• Gleave M.E., Miyake H., Zellweger T., Chi K., July LV., Nelson C., Rennie P.: Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin, to enhance androgen- and chemo-sensitivity in Prostate cancer. Urology 58 (2) Suppl 1 (2001)
• Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., Gleave M.E.: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia 3 (4): 360-367 (2001)
• Miyake H., Hara S., Zellweger T., Kamidono S., Gleave M.E., Hara I.: Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. Molecular Urology 5 (3): 105-111 (2001)
• Zellweger T., Ackermann D.: Abklärung und Rezidivprophylaxe der Nephrolithiasis. Ärztejournal für die Schweiz 3, 35-37 (1999)
• Neuhaus M., Wagner U., Schmid U., Ackermann D., Zellweger T., Maurer R., Alund G.,Knönagel H., Rist M., Moch H., Mihatsch M.J., Gasser Th.C., Sauter G.: Polysomy 1 and 17 but not Y chromosome losses have prognostic significance in superficial urinary bladder cancer. Human Pathology 30 (1): 81-86 (1999)
• Wagner U., Süess K., Schmid U., Ackermann D., Zellweger T., Maurer R., Alund G., Knönagel H., Rist M., Jordan P., Moch H., Mihatsch M.J., Gasser Th. C., Sauter G.: Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. Journal of Pathology 188 (1): 44-50 (1999)
• Zhao J., Richter J., Wagner U., Roth B., Schraml P., Zellweger T., Ackermann D., Schmid U., Moch H., Mihatsch M.J., Gasser T.C., Sauter G.: Chromosomal imbalances in noninvasive bladder neoplasms (pTa). Cancer Research 15, 59 (18): 4658-4661 (1999)
• Zellweger T., Grob R., Buhl D., Müller J., Ackermann D.: Analyse von Harnwegsinfekten in der Ostschweiz 1993 -1995. Aktuelle Urologie 2, 67-70 (1998)